Danaher Launches Beacon Initiative and Its First Partnership Focused on Gene Therapy Innovation WASHINGTON, Nov. 10, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR), a global science and technology innovator, today announced that it has entered a strategic partnership with Duke University to form its first Danaher Beacon for Gene Therapy Innovation. Danaher Beacons is a... Read more
WASHINGTON, Oct. 20, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the third quarter 2022. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended September 30, 2022, net earnings were $1.6 billion, or $2.10 per diluted common share which represents a 36.0% year-over-year... Read more
Danaher Releases 2022 Sustainability Report and Announces New Greenhouse Gas Emissions Reduction Target WASHINGTON, Oct. 5, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”), the global science and technology innovator, today published its 2022 Sustainability Report which highlights the progress of the Company’s sustainability program. Danaher also announced it has set a new goal to... Read more
WASHINGTON, Sept. 20, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2022 on Thursday, October 20, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying slide presentation will be webcast on the “Investors” section of... Read more
Danaher Announces Intention to Separate Environmental & Applied Solutions Segment to Create an Independent, Publicly Traded Company WASHINGTON, Sept. 14, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) today announced its intention to separate its Environmental & Applied Solutions segment to create an independent, publicly traded company. The new company will be comprised of Danaher’s Water... Read more
WASHINGTON, Sept. 1, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) will host a live video webcast of its Bioprocessing Investor and Analyst Meeting at Cytiva on September 15, 2022 beginning at approximately 12:00 p.m. ET. The event will be held at Danaher’s Cytiva facility in Marlborough, Massachusetts and hosted by Rainer M. Blair, President &... Read more
WASHINGTON, D.C., July 21, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”) today announced results for the second quarter 2022. All results in this release reflect only continuing operations unless otherwise noted. For the quarter ended July 1, 2022, net earnings were $1.7 billion, or $2.25 per diluted common share which represents a 1.5%... Read more
WASHINGTON, June 29, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that it has appointed Feroz Dewan to its Board of Directors and to the Board’s Science & Technology Committee. This addition expands the size of Danaher’s Board from thirteen to fourteen members. Mr. Dewan is currently CEO of Arena Holdings Management, a global... Read more
WASHINGTON, June 21, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the second quarter 2022 on Thursday, July 21, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour. The call and an accompanying slide presentation will be webcast on the “Investors” section of... Read more
Consortium aims to speed the development and delivery of customized or ‘bespoke’ gene therapies WASHINGTON, May 12, 2022 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that it has joined the Bespoke Gene Therapy Consortium (BGTC). Launched in October 2021, the BGTC will generate gene therapy resources that the research community can use to streamline gene... Read more